Table 1 Demographic and baseline clinical data
bDMARDS group (n = 55) | MTX group (n = 66) | Control group (n = 28) | p value | |
|---|---|---|---|---|
Age, years | 53.5 | 57.0 | 64.4 | n.s |
Female sex (%) | 70.1 | 75.8 | 75.0 | n.s |
Disease duration, years | 5.8** †† | 1.8 | 0.9 | < 0.01 |
DAS28-ESR at baseline | 4.36 | 3.96 | 3.75 | n.s |
CDAI at baseline | 17.4** | 15.9** | 11.6 | < 0.01 |
Steinbrocker stage | ** †† | < 0.01 | ||
I | 22 | 56 | 19 | |
II | 17 | 5 | 9 | |
III | 9 | 4 | 0 | |
IV | 7 | 1 | 0 | |
Steinbrocker class | ** †† | < 0.01 | ||
1 | 17 | 44 | 19 | |
2 | 30 | 22 | 9 | |
3 | 7 | 0 | 0 | |
4 | 1 | 0 | 0 | |
MTX (%) | 76.3** | 100** | 0 | < 0.01 |
MTX dose (mg/week) | 6.8 | 7.2 | 0 | n.s |
Glucocorticoid (%) | 40.0 | 24.2 | 25.0 | n.s |
SASP (%) | 41.8*† | 66.7 | 75.0 | < 0.01 |
BUC (%) | 23.6*†† | 59.1 | 53.6 | < 0.01 |
IGU (%) | 14.7 | 12.1 | 25.0 | n.s |
TAC (%) | 5.4 | 0.0 | 3.6 | n.s |
bDMARDs group | 55 cases | |||
|---|---|---|---|---|
TCZ | 20 | |||
GLM | 16 | |||
ETN | 13 | |||
CZP | 3 | |||
ABT | 2 | |||
IFX | 1 |